analysis of your results? 8) It is great that you want to contact study authors for clarification. However, this chances of getting data from studies published over 10-15 years ago may be low. Perhaps you want to consider adding a year cutoff for when you would do this for. 9) Currently your methods state that if there are multiple time points the one measured at the longest time interval will be selected. I think this depends on your outcome. I think it would be helpful to define whether you're interested in acute vs delayed CINV or both and give time points based on this. With adverse events, it may be more helpful to use the time point closest to when the CAM therapy was last administered vs the longest time point.
REVIEWER
Mary Baron Nelson Keck School of Medicine at USC USA REVIEW RETURNED 24-Jun-2019
GENERAL COMMENTS
This paper, describing the protocol to be followed for a systematic review of complementary and alternative therapies used for nausea and vomiting in children with cancer, meets a need for more information on this science and will fill a gap in the literature. The protocol provides most of the necessary information as outlined in the PRISMA-P checklist, is well-organized and flows logically. The references cited are up to date and relevant to the topic. The strength of the paper is that the very detailed explanation of each step of this process provides an excellent resource to other nurses/institutions who may want to develop and implement a similar program. iii. On page 9, planned dates between which the search would be conducted are not included. iv. There are minor grammatical errors throughout the paper, and the authors should engage an editor for corrections.
VERSION 1 -AUTHOR RESPONSE

Reviewer 1
Comment 1 This systematic review and meta-analysis has the potential to address the question of whether CAM therapies have any role for nausea and vomiting in children with cancer. However, I think the study objective and outcomes need to be more clearly defined to have a meaningful and clear result. I think the intent is there, it just needs to be more specific.
Response 1
Many thanks for your positive comments. The study objective (Page 9) and outcomes (Page 10) have been refined according to your comments.
Comment 2
In the introduction section (page 7) under description of interventions. I think you meant to say that CAM therapies are "NOT" a part of standard care.
Response 2
We are so sorry for the mistake. The sentence (Page 6) has been amended accordingly.
Comment 3
The objective states to synthesize the evidence of CAM on nausea and vomiting in children with cancer. Is this chemotherapy-induced nausea and vomiting? radiation? other causes? To just have nausea and vomiting in any child with cancer is quite broad and will not be as helpful to the reader trying to apply the results to their patient. It would be more useful to pick the cause of the nausea and vomiting in the child with cancer and it will also help focus the search and your results.
Response 3
Thank you so much for your constructive comments. In fact, when planning this systematic review, we also thought about using a more specific term, e.g. chemotherapy-induced nausea and vomiting (CINV). However, nausea and vomiting can be attributed to various factors [1] and caused by different cancer treatment. [ If it is chemotherapy-induced nausea and vomiting you're interested in, why not define nausea and vomiting time points in your outcomes? Acute vs delayed phase.
Response 4
As mentioned in our response to your comment 3, we planned to adopt a relatively board term 'treatment-related nausea and vomiting' in this systematic review so as to include all relevant studies which examined the effectiveness of CAM on nausea and vomiting induced or caused by cancer treatment. The results of this systematic review can therefore determine the overall effectiveness of CAM on treatment-related nausea and vomiting among children with cancer which is an underresearched area. However, we also understand the importance of evaluating the effectiveness of CAM on specific type of nausea and vomiting, i.e. CINV. The results will be useful to guide healthcare professionals what CAM should be applied when taking care of pediatric patients who undergo a specific type of cancer treatment. Therefore, subgroup analyses will be conducted to generate evidence on the effectiveness of CAM on nausea and vomiting by cancer treatment, e.g. chemotherapy and radiotherapy (Page 19). The pathophysiology of CINV is well-established in existing literature. [1] There is also a clear classification for CINV: anticipatory (within 24 hours before chemotherapy administration), acute (occurring within 24 hours of chemotherapy administration), and delayed (occurring in 24 hours to 7 days after chemotherapy administration). [2, 3] When compared to CINV, nausea and vomiting caused by radiotherapy (RINV) are less severe, but more prolong in some patients. [4] Since the number of studies regarding CINV is more than RINV, the pathophysiology of RINV is less understood. [5] Also, there is no a clear classification for RINV. Given that the major objective of this systematic review is to determine the overall effectiveness of CAM on treatmentrelated nausea and vomiting, we did not specify the time points of outcome measures using the classification of CINV (i.e. anticipatory, acute and delay) in the primary analysis as the onset and duration of nausea and vomiting may vary depending on types of cancer treatment.
[6] However, when performing the subgroup analysis to evaluate the effectiveness of CAM on CINV, the outcomes will be defined by time points (i.e. anticipatory, acute and delay) based on the classification of CINV. With respect to the types of studies that are being included, I would suggest specifying if the articles need to be fully published or did you want to include conference abstracts?
Response 5
This review will only include the articles that are fully published. To clarify, the manuscript (Page 9) has been revised as follows, "To be included in this review, the article must be a fully published randomized trial."
Comment 6
With respect to the age group. Perhaps clarify if you want 'all' study participants in the included studies to be less than 18 years.
Response 6
Yes, all study participants in the included studies must be aged ≤ 18. To clarify, the manuscript (Page 9) has been amended accordingly.
Comment 7
You state any adverse event as a secondary outcome. This seems quite broad given that many of the AE reported will likely be due to chemotherapy being administered. Perhaps specify AE's that are thought by study authors to be due to CAM Response 7
Any adverse event is defined as an unfavorable and unintended sign or symptom that occurs during the use of CAM but is not necessarily caused by it. [1] The most commonly reported adverse events of CAM Response 9 Thanks for your suggestion. To increase the chance of success in getting the data from the authors, we will only contact them for clarification if the studies have been published within the last 10 years. The manuscript (Page 14) has been amended accordingly.
Comment 10
Currently your methods state that if there are multiple time points the one measured at the longest time interval will be selected. I think this depends on your outcome. I think it would be helpful to define whether you're interested in acute vs delayed CINV or both and give time points based on this. With adverse events, it may be more helpful to use the time point closest to when the CAM therapy was last administered vs the longest time point.
Response 10
Since this systematic review aims to evaluate the overall effectiveness of CAM on nausea and vomiting among children with cancer, we adopted a relatively board term 'treatment-related nausea and vomiting' as our outcome measures. However, the onset and duration of nausea and vomiting are highly dependent on cancer treatment. [1] While there is a well-established classification for CINV, no such classification exists for RINV. After a thorough discussion, we therefore decided to select the outcomes measured at the longest time interval for our primary analysis. We indeed understand the importance of evaluating the effectiveness of CAM on specific type of nausea and vomiting, i.e. CINV. The results can guide healthcare professionals what CAM should be applied when taking care of pediatric patients who undergo a specific type of cancer treatment. Therefore, subgroup analyses will be conducted by cancer treatment, i.e. chemotherapy and radiation. For the subgroup analysis on the effectiveness of CAM on CINV, we will analyze the data by different time points, i.e. anticipatory, acute and delay as there is a well-recognized classification of CINV. To clarify, the manuscript (Page 14 and 19) has been amended accordingly. You may also refer to our responses to your comment 3 and 4. Thank you so much for your comments on how to evaluate the adverse events. We have carefully read the existing literature on how adverse events should be recorded and analyzed. According to a recent metaanalysis of adverse events in randomized controlled trials, the authors suggested that, only adverse events which occurred during intervention period will be included in analysis. Those occurred during follow-up (non-intervention) period shall be excluded. [ Reviewer 2 Comment 1 This paper, describing the protocol to be followed for a systematic review of complementary and alternative therapies used for nausea and vomiting in children with cancer, meets a need for more information on this science and will fill a gap in the literature. The protocol provides most of the necessary information as outlined in the PRISMA-P checklist, is well-organized and flows logically. The references cited are up to date and relevant to the topic. The strength of the paper is that the very detailed explanation of each step of this process provides an excellent resource to other nurses/institutions who may want to develop and implement a similar program.
should engage an editor for corrections.
Response 5
Many thanks for your comment. The manuscript has been sent to professional editing for corrections. 
